Literature DB >> 29641951

Priorities in the Cardiovascular Care of Breast Cancer Survivors.

Bonnie Ky1.   

Abstract

Breast cancer is the most common malignancy in women with more than 3 million breast cancer survivors in the United States alone. Survivors of breast cancer suffer from an increased burden of cardiovascular risk factors and disease. The focus of this review is to describe the epidemiology of cardiovascular disease in breast cancer survivors, including the cardiovascular concerns observed with common cancer therapies. Strategies to improve upon the early detection and treatment of cardiovascular disease, including clinical prediction algorithms, biomarkers, and imaging measures are also reviewed, and the use of cardioprotective therapies to mitigate risk are summarized. Finally, the need for evidence-based research to inform and improve upon the multidisciplinary care of this growing population is highlighted.

Entities:  

Mesh:

Year:  2018        PMID: 29641951      PMCID: PMC6804837          DOI: 10.1200/JOP.18.00027

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.714


  45 in total

1.  The incidence and functional consequences of RT-associated cardiac perfusion defects.

Authors:  Lawrence B Marks; Xiaoli Yu; Robert G Prosnitz; Su-Min Zhou; Patricia H Hardenbergh; Michael Blazing; Donna Hollis; Pehr Lind; Andrea Tisch; Terence Z Wong; Salvador Borges-Neto
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-09-01       Impact factor: 7.038

2.  Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.

Authors:  Edith Pituskin; John R Mackey; Sheri Koshman; Davinder Jassal; Marshall Pitz; Mark J Haykowsky; Joseph J Pagano; Kelvin Chow; Richard B Thompson; Larissa J Vos; Sunita Ghosh; Gavin Y Oudit; Justin A Ezekowitz; D Ian Paterson
Journal:  J Clin Oncol       Date:  2016-11-28       Impact factor: 44.544

3.  Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

Authors:  Daniela Cardinale; Alessandro Colombo; Giulia Bacchiani; Ines Tedeschi; Carlo A Meroni; Fabrizio Veglia; Maurizio Civelli; Giuseppina Lamantia; Nicola Colombo; Giuseppe Curigliano; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2015-05-06       Impact factor: 29.690

4.  Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations With Ejection Fraction Decline, Recovery, and Heart Failure Symptoms Over 3 Years of Follow-Up.

Authors:  Hari K Narayan; Brian Finkelman; Benjamin French; Theodore Plappert; David Hyman; Amanda M Smith; Kenneth B Margulies; Bonnie Ky
Journal:  Circulation       Date:  2017-01-19       Impact factor: 29.690

5.  Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.

Authors:  Mark Ledwidge; Joseph Gallagher; Carmel Conlon; Elaine Tallon; Eoin O'Connell; Ian Dawkins; Chris Watson; Rory O'Hanlon; Margaret Bermingham; Anil Patle; Mallikarjuna R Badabhagni; Gillian Murtagh; Victor Voon; Leslie Tilson; Michael Barry; Laura McDonald; Brian Maurer; Kenneth McDonald
Journal:  JAMA       Date:  2013-07-03       Impact factor: 56.272

6.  Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.

Authors:  Bonnie Ky; Mary Putt; Heloisa Sawaya; Benjamin French; James L Januzzi; Igal A Sebag; Juan Carlos Plana; Victor Cohen; Jose Banchs; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie
Journal:  J Am Coll Cardiol       Date:  2013-11-27       Impact factor: 24.094

7.  Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities.

Authors:  Nonniekaye Shelburne; Bishow Adhikari; Joanna Brell; Myrtle Davis; Patrice Desvigne-Nickens; Andrew Freedman; Lori Minasian; Thomas Force; Scot C Remick
Journal:  J Natl Cancer Inst       Date:  2014-09-10       Impact factor: 13.506

8.  Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

Authors:  Thomas M Suter; Marion Procter; Dirk J van Veldhuisen; Michael Muscholl; Jonas Bergh; Chiara Carlomagno; Timothy Perren; Rodolfo Passalacqua; Claudia Bighin; Jan G M Klijn; Fail T Ageev; Erika Hitre; Juergen Groetz; Hiroji Iwata; Malgorzata Knap; Michael Gnant; Susanne Muehlbauer; Alison Spence; Richard D Gelber; Martine J Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2007-07-23       Impact factor: 44.544

9.  Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study.

Authors:  Saro H Armenian; Lanfang Xu; Bonnie Ky; Canlan Sun; Leonardo T Farol; Sumanta Kumar Pal; Pamela S Douglas; Smita Bhatia; Chun Chao
Journal:  J Clin Oncol       Date:  2016-02-01       Impact factor: 44.544

Review 10.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Authors:  S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto
Journal:  Lancet       Date:  2011-10-19       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.